SARTF (Sartorius AG) Construction In Progress: $0 Mil (As of Mar. 2026)


SARTF Sartorius AG SARTF
85 GF Score
Price $192.43
GF Value $226.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sartorius AG Construction In Progress?

Sartorius AG SARTF -1.83% 85 Construction In Progress is $0 Mil as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Sartorius AG's quarterly construction in progress increased from Sep. 2025 ($0 Mil) to Dec. 2025 ($702 Mil) but then declined from Dec. 2025 ($702 Mil) to Mar. 2026 ($0 Mil).

Sartorius AG's annual construction in progress increased from Dec. 2023 ($718 Mil) to Dec. 2024 ($759 Mil) but then declined from Dec. 2024 ($759 Mil) to Dec. 2025 ($702 Mil).

Sartorius AG Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sartorius AG's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Construction In Progress Chart

Sartorius AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 361.36 553.92 718.21 759.16 701.76

Sartorius AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 701.76 0.00
SARTF
85GF Score
Sartorius AG SARTF
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius AG Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0 Mil mean?
Sartorius AG (SARTF) has a Construction In Progress of $0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Sartorius AG and its competitors.
Is Sartorius AG's Construction In Progress too high?
Sartorius AG's current Construction In Progress is $0 Mil. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Construction In Progress compare to ISRG and BDX?
Sartorius AG's Construction In Progress of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Devices & Instruments company?
A good Construction In Progress depends on the Medical Devices & Instruments industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sartorius AG and its competitors. Sartorius AG's current Construction In Progress is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current Construction In Progress is $0 Mil. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Construction In Progress is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for SARTF:

  • Construction In Progress: $0 Mil
  • GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score

Get the complete analysis for SARTF

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$192.43
Price
$226.12
GF Value